Status:
COMPLETED
Prolactin Receptor and Breast Diseases
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut Pasteur
Conditions:
Benign Breast Disease
Breast Cancer
Eligibility:
FEMALE
10+ years
Brief Summary
Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes. T...
Detailed Description
There is currently no known genetic disease linked to prolactin (prl) or its receptor (prlR) in humans. In a previous work, we have identified a new mutation of prolactin receptor that leads to it's c...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- benign breast diseases
- 10 \< age \< 25 for simple FA
- 10 \< age \< 50 for other diseases .no hormonal treatment for at least 3 months if patients took cyproterone acetate; 1 month for other ovaries-interfering hormonal treatment, and 1 week for ovaries-non-interfering hormonal treatments.
- Signature of the informed consent form (icf) by patients or their legal representative (for patients under age of 18.)
- breast cancer :
- having a breast cancer with a planned surgery
- age \> 55 years
- post menopausal with not menopause substitution treatment
- signature of the icf
- control group :
- 18 \< age \< 60
- signature of the icf
- Exclusion criteria :
- no signature or no conformity of the icf
- no social security
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
735 Patients enrolled
Trial Details
Trial ID
NCT00842465
Start Date
September 1 2008
End Date
June 1 2012
Last Update
November 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié Salpêtrière Hospital
Paris, France, 75013